SteatoSITE is a Data Commons that will combine genomic (RNA-Seq), imaging, and clinical information from patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

It’s estimated that 20-30% of the world’s adult population has NAFLD, which is an accumulation of excess fat in the liver of people who drink little or no alcohol.  Strongly linked to type II diabetes and obesity, it is the most common cause of chronic liver disease in developed countries, and there is currently no approved treatment.  Chronic liver disease is now the 3rd most common cause of premature death in the United Kingdom.  The progressive form of NAFLD, NASH, usually precedes liver fibrosis, liver cancer, and premature death.  Early recognition of the disease, biomarkers to monitor progression, and effective treatments, are all urgently required in order to reduce deaths from end-stage liver disease.

Utilising Scotland’s unified health data to assemble genomic  (RNA-Seq) and clinical data, as well as information from FibroScans and pathology, from 1000 patients, SteatoSITE will be the world’s first NASH data commons, and enable a deeper understanding of the disease processes.